CSNK1E: Casein kinase I isoform epsilon
Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates (Probable).
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CSNK1E, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| UmbralisibWithdrawn | Approved | TG Therapeutics | Small molecule | InhibitorCasein kinase I epsilon inhibitor | 4 |
| Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | Umbralisib | Phase 2 | Active, not recruiting | City of Hope Medical Center | Mar 5, 2021 |
| Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | Umbralisib | Phase 2 | Active, not recruiting | Jennifer R. Brown, MD, PhD | Nov 12, 2020 |
| Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | Umbralisib | Phase 1 | Active, not recruiting | University of Chicago | Sep 14, 2017 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | Umbralisib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Sep 1, 2017 |
- Follicular lymphoma0.52
- Marginal zone lymphoma0.48
- Neoplasm0.39
- Neurodegenerative disease0.37
- B-cell chronic lymphocytic leukemia0.34
- X-linked spasticity-intellectual disability-epilepsy syndrome0.33
- Developmental and epileptic encephalopathy, 10.33
- Diffuse large B-cell lymphoma0.24
- Mantle cell lymphoma0.21
- Hypotensive disorder0.21
- Cachexia0.20
- Ovarian neoplasm0.19
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4937, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P49674, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets